Obesity and Drug Dosing: Clinical Pharmacology Considerations; Request for Comments

William C. Zamboni, a researcher at UPMC Hillman Cancer Center, supports the need for further study on how body size and composition affect the clearance of complex drugs like biologics. He argues that current weight-based dosing may lead to under-dosing in obese patients and calls for the development of new metrics and biomarkers to optimize dosing.

An individual with a family member affected by obesity supports the action of considering obesity in clinical pharmacology. They argue that the agency should look beyond BMI to factors like body composition and include more individuals with obesity in clinical trials to ensure safer and more effective dosing.